MBMaurizio Barbera

Maurizio Barbera

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maurizio Barbera has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Data-Driven Motion Correction of 11 C-Methionine PET Images on a Cohort of Pediatric Patients With Brain Tumor in a PET/MRI Study

    by Ilaria Neri, Matthew Spangler-Bickell, Federico Fallanca, Giovanna Gattuso, Maurizio Barbera, Samuele Ghezzo, Carolina Bezzi, Paola Mapelli, Sara Pizzamiglio, Paolo Verderio, et al.

    A data-driven head Motion Correction (MoCo) method was tested on 11C-Methionine brain PET images in a cohort of 44 pediatric patients with brain tumors referred to a PET/MR study. Its impact was investigated both qualitatively and quantitatively. For each patient, PET images were reconstructed offline both with (PETddMoCo) and without (PETnoMoCo) MoCo algorithm. An expert Nuclear Medicine physician qualitatively evaluated PET images, and segmented PET positive lesions in both datasets, extracting the following PET parameters: maximum and mean Standardized Uptake Value (SUVmax and SUVmean, respectively), and Metabolic Tumor Volume (MTV). PET parameters before and after MoCo were compared and their absolute percentage difference was calculated (%). Contrast-to-Noise (CNR) and its difference () before and after MoCo were calculated. Thirty-one patients had a “low” level of motion, 8 patients “medium” and 5 patients “high”. Twenty-one patients out of forty-four had positive 11C-Methionine uptake (26 lesions). Qualitatively, no difference was evident in negative patients, while two PET positive lesions could be better defined after motion correction. Quantitatively, CNR increased significantly after motion correction for “medium+high” lesions, while none of the PET parameters showed significant difference. Increasing the sample of patients might confirm these results.


  • Open Access

    Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomized Controlled Trial

    by Sabrina Gloria Giulia Testoni, Maria Chiara Petrone, Michele Reni, Gemma Rossi, Maurizio Barbera, Valeria Nicoletti, Simone Gusmini, Gianpaolo Balzano, Walter Linzenbold, Markus Enderle, et al.

    Endoscopic ultrasound-ablation with HybridTherm-Probe (EUS-HTP) significantly reduces tumour volume (TV) in locally-advanced pancreatic ductal adenocarcinoma (LA-PDAC). We aimed at investigating the clinical efficacy of EUS-HTP plus chemotherapy versus chemotherapy (HTP-CT and CT arms) in LA- and borderline-resectable (BR) PDAC, with 6-months progression-free survival (6-PFS) rate as primary endpoint. In a phase-II randomized-controlled-trial, 33 LA/BR-PDAC patients per-arm were planned to verify 20% improved 6-PFS rate. Radiological response (Choi criteria), TV and serum CA19.9 were assessed up to 6-months. Seventeen and 20 LA/BR-PDAC patients were randomized to HTP-CT or CT. Baseline and CT-related features were balanced. At 6-months, 6-PFS rate was 41.2% and 30% in HTP-CT and CT arms (p = 0.48), respectively. A decrease ≥50% of serum CA19.9 was achieved in 75% and 64.3% of HTP-CT and CT patients (p = 0.53), respectively. TV reduced up to 6-months in 64.3% and 47.1% of HTP-CT and CT patients (p = 0.35), respectively. Resection rate, PFS-time and overall survival (OS-time) were similar. HTP-CT achieves a non-significant 11.2%, 10.7% and 17.2% improved 6-PFS, CA19.9 decrease ≥50% and TV reduction rates over CT, without any impact on resection rate, PFS-time and OS-time. As the study was underpowered, these results suggest further investigation of EUS-local ablation in selected patients with localized disease after induction CT.


  • Generative Adversarial Networks to Synthesize Missing T1 and FLAIR MRI Sequences for Use in a Multisequence Brain Tumor Segmentation Model

    by Gian Marco Conte, Alexander D. Weston, David C. Vogelsang, Kenneth A. Philbrick, Jason C. Cai, Maurizio Barbera, Francesco Sanvito, Daniel H. Lachance, Robert B. Jenkins, W. Oliver Tobin, et al.

    Brain MRI scans synthesized using generative adversarial networks can be used as inputs in an existing deep learning model, thus allowing for their application in case MRI data are missing. Background Missing MRI sequences represent an obstacle in the development and use of deep learning (DL) models that require multiple inputs. Purpose To determine if synthesizing brain MRI scans usi...


  • Open Access

    A STANDARDIZED LONGITUDINAL DCE AND DSC PERFUSION MRI PROTOCOL TO PREDICT THE PROGNOSIS OF PATIENTS TREATED FOR GLIOBLASTOMA

    by Maurizio Barbera

    Introduction: Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumor in adults; it is characterized by a poor overall survival (OS) despite the standard treatment of maximum safe resection followed by the Stupp protocol, that includes both chemo- and radiotherapy. In the past, the role of perfusion techniques such as Dynamic Susceptibility Contrast (DSC)

  • EUS-GUIDED CRYOTHERM ABLATION OF STAGE III PANCREATIC ADENOCARCINOMA: A PRELIMINARY RADIOLOGICAL PERSPECTIVE

    by E Dabizzi, Sg Giulia Testoni, M Barbera, W Linzenbold, MC Petrone, M Enderle, F De Cobelli, R Nicoletti, S Gusmini, G Rossi, et al.

    Aims: Cryotherm ablation is a hybrid bipolar ablative technique, combining radiofrequency thermal injury with a cryogenic gas. However, data on radiological perspectives are still lacking. Aim: To evaluate differences in MDCT and DW-MRI imaging on tumor size and necrosis induced by the ERBE HybridTherm (HTP) probe. Methods: We evaluated consecutive patients with stage III pancreatic adenocarcinoma presented at our center from 02/2015 and 10/2017. These pts were enrolled in an ongoing randomized-controlled trial, belonging to chemotherapy+HTP treatment group. HTP ablation was conducted up to 3 times at 1-month interval. Patients underwent MDCT and DW-MRI scan 72h after treatment and at T0 and 2, 4 and 6 months after treatment began. We assessed the difference in tumor and ablation size and volume between CT and MRI. Data were considered for analysis if both imaging techniques were available for the same date. The paired T-Test and the Wilcokson matched-pairs signed rank test were used for statistical analysis. Results: 15 patients (mean age 63 ± 11 years) underwent HTP treatment (mean 2.2 per pt) for locally advanced (11 pts) and borderline resectable (4 pts) disease. In 3 pts MRI was not feasible. A total of 41 MDCT and DW-MRI scans were identified. We observed no difference in tumor size between CT and MRI (p = 0.816 for long axis and p = 0.313 for short axis) as well as between MRI and ADC-Map (p = 0.120 and p = 0.431). Linear regression analysis for the comparison of both CT/MRI and MRI/ADC-Map showed a p =< 0.001. We reported a significant difference between CT and MRI size of the ablation zone, for both long and short axis (p = 0.0029). Conclusions: These data highlighted the agreement of both CT and MRI in tumor evaluation, whereas a significant difference in the evaluation of ablation necrosis, suggesting that DW-MRI with ADC-Map is essential in necrosis detection in responder patients.

  • P.08.4 EUS-GUIDED CRYOTHERM ABLATION OF STAGE III PANCREATIC ADENOCARCINOMA: A PRELIMINARY RADIOLOGICAL PERSPECTIVE

    by E. Dabizzi, S. Testoni, M. Barbera, M.C. Petrone, W. Linzenbold, M. Enderle, F. De Cobelli, R. Nicoletti, S. Gusmini, G. Rossi, et al.